Prosecution Insights
Last updated: November 20, 2026
Application No. 19/065,116

DOSE REGIMEN OF VICASINABIN

Non-Final OA §103§112
Filed
Feb 27, 2025
Priority
Sep 01, 2022 — EU 22193362.5 +2 more
Examiner
CHONG, YONG SOO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
2y 2m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
392 granted / 894 resolved
-16.2% vs TC avg
Strong +42% interview lift
Without
With
+41.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
62 currently pending
Career history
963
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
52.7%
+12.7% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 894 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 11-20 are pending and are examined herein. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112(b): The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 11 is rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claim recites a “method for the treatment” but does not recite any disorders, diseases, or conditions. For the purposes of compact prosecution, the diseases recited in the dependent claims will be used for examination. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 11-20 are rejected under 35 U.S.C. 103 as being unpatentable over Adam et al. (US Patent 9,056,866) in view of Bartels et al. (US Patent Application 2006/0257391). The instant claims are directed to a method for the treatment or prevention of non-proliferative diabetic retinopathy (NDPR) by administering (S)-1-[5-tert-Butyl-3-(1-methyl-1H-tetrazol-5-ylmethyl)-3H-[1,2,3]triazolo- [4,5-d]pyrimidin-7-yl]-pyrrolidin-3-ol (vicasinabin) in combination with another treatment for diabetic retinopathy. Adam et al. teach methods of treating or prophylaxis of diabetic retinopathy (col. 3, lines 55-57) by administering an effective amount of a compound of formula I (abstract; col. 27, line 49 to col. 28, line 9). A preferred compound is vicasinabin in Example 151 (col. 111, lines 5-35). Oral administration is taught (col. 28, lines 55-56). However, Adam et al. fail to disclose specifically NDPR, the claimed dose, and another treatment for diabetic retinopathy. Bartels et al. teach a method of treating NDPR by administering a serine proteinase enzyme (abstract). Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, prior to the effective filing date of the claimed invention, to have combined vicasinabin, as taught by Adam et al., in the claimed amounts, with serine proteinase enzyme, in the method of treating NDPR, as taught by Bartels et al. A person of ordinary skill in the art would have been motivated to combine vicasinabin with serine proteinase enzyme because both are individually known to be useful for treating diabetic retinopathy. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating NDPR by the therapeutically additive effect of two known active agents being used for the same purpose. Moreover, the claimed amounts are obvious absent a showing of criticality or unexpected results in view of Adam’s teaching that the compound of formula I must be administered in an effective amount. Generally, mere optimization of ranges will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “When the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimal or workable ranges by routine experimentation. In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); “The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.” In re Peterson, 315 F. 3d at 1330, 65 USPQ 2d at 1382; lt has been held that it is within the skills in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. In re Boesch, 205 USPQ 215 (CCPA 1980) MPEP 2114.04 Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free). /Yong S. Chong/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Feb 27, 2025
Application Filed
Nov 05, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778957
COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION
3y 5m to grant Granted Nov 03, 2026
Patent 12734158
APPLICATION OF RILUZOLE- AND BORNEOL-CONTAINING COMPOSITION IN PREPARATION OF MEDICATION FOR TREATING CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 15, 2026
Patent 12721846
METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA
4y 3m to grant Granted Sep 01, 2026
Patent 12714700
METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES
2y 5m to grant Granted Aug 25, 2026
Patent 12691087
METHOD OF ENHANCING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM
7y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
86%
With Interview (+41.7%)
3y 11m (~2y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 894 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month